Amrif

Amrif is a private, preclinical-stage biotech developing RESCAP, an oral alkaline phosphatase enzyme replacement therapy, targeting the root causes of multiple age-related diseases. The company's approach is grounded in scientific literature suggesting AP is crucial for gut barrier integrity, inflammation control, and longevity, with animal data showing lifespan extension. Amrif aims to translate these findings into a safe, natural, and broadly applicable therapeutic to improve healthspan. The company is led by a small team of seasoned experts and appears to be in the early stages of asset development and fundraising.

Oral alkaline phosphatase (AP) enzyme replacement therapy targeting gut barrier integrity and systemic inflammation as a root cause of multiple age-related diseases.

Amrif operates in the competitive longevity and anti-inflammaging space, competing with companies developing senolytics (e.g., Unity Biotechnology), mTOR inhibitors, and other gut-microbiome therapies. Its specific focus on alkaline phosphatase is niche, but it must demonstrate superior efficacy or a clearer path to approval versus broader approaches.